Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
Press Releases
Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
Operational Updates – February 2024
Operational Updates – February 2024
Operational Updates – October 2023
Operational Updates – October 2023
Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit
Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit
Singapore’s Ministry of Health grant license approval for commercial use for Onco-PDO™ – Personalized Cancer Drug Screening
Singapore’s Ministry of Health grant license approval for commercial use for Onco-PDO™ – Personalized Cancer Drug Screening
International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.
The two research institutes in this collaboration are both located in the Hong Kong Science Park, including the LSCCB funded by the Innovation and Technology Commission’s Health@InnoHK innovation platform, and the Hong Kong Science and Technology Park Corporation partner company Invitrocue (Hong Kong). Read More (English)Read More (Traditional Chinese)Read More (Simplified Chinese) This event has …
Operational Updates and Management Accounts
Operational Updates and Management Accounts
Quarterly Updates – March 2021
Quarterly Updates – March 2021
IVQ launches Personalised Cancer Screening Service Onco-PDO
Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™